Business Wire

World First at Maria Middelares Hospital in Belgium Thanks to da Vinci SP’s Innovative Technology

29.5.2024 15:37:00 EEST | Business Wire | Press release

Share

As part of the new Health Value Space Ghent, Maria Middelares Hospital continues to lead the way as a “smart” hospital, poised to deliver healthcare of the future to its patients. The new da Vinci SP (single port) surgical system has now been in use since May 21, making complex surgery even less invasive, via a single incision. It was on May 27 that a world first took place at the hospital: a kidney autotransplantation assisted by the da Vinci SP surgical system.

The arrival of Intuitive’s new da Vinci SP system aligns perfectly with Maria Middelares' vision of developing a patient-oriented robotics platform. The SP enables more complex procedures to be performed through a single incision or natural orifice. Over 400 peer-reviewed publications demonstrate the safety, efficacy, and excellent results of this cutting-edge technology. The da Vinci SP offers incredible value on a daily basis for Maria Middelares and its patients.

  • A World First

On May 27, urologist Prof. dr. Decaestecker achieved a world first. Using the da Vinci SP, he performed an intracorporeal kidney autotransplantation on an 18-year-old woman suffering from a complex ureteral lesion, with severe damage to the ureter between the kidney and the bladder. The best solution for the patient was to bridge the major defect in the ureter by moving the kidney closer to the bladder. This technique is called autotransplantation.

The transplantation was achieved intracorporeally, meaning entirely inside the body. Prof. dr. Decaestecker has perfected this technique, having performed such operations since 2017 (a European first at the time) using the da Vinci Multiport system, equipped with four robotic arms. The advantage of an in-body operation is that no large incisions are required to move the kidney in and out of the body; only a few small incisions (with the Multiport) of around 1 cm were needed to introduce the robotic instruments.

Prof. dr. Decaestecker explains: What’s new now is the combination of in-body grafting with a single incision thanks to the SP robotic system, which has just one articulated arm. This is less intrusive for the patient’s body and should also facilitate smoother post-op recovery. Other advantages are that we can perform the procedure entirely outside the abdomen, allowing the patient to lie flat on their back in a natural position. This is important as the patient can now be operated on in a more comfortable position, therefore with fewer intestinal complications.”

  • What does the future hold?

With the development of a robotics platform, Maria Middelares aims to optimize the use of robotic systems within the operating room as much as possible. The goal is to improve operating room efficiency and patient outcomes. These innovative surgical systems allow for further personalization of surgery based on patient needs.

Dr. Ameye, Director of Innovation, adds: “In our organization, we strive to seek out the best technology combined with in-depth monitoring. We map the quality of care using big data analysis based on a multitude of uniform data. This enables us to identify areas for improvement and continuously optimize our care. Providing value-based healthcare is our main motivation.”

You can download images from the operating room of this world premiere via this link.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information

Catherine Zenner, Head of Communications Maria Middelares
catherine.zenner@mijnziekenhuis.be or 0478 99 53 11.

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.

Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye